Future Events
|
||
Important LifeTime consortium perspective article in Nature, co-authored by Chris MarineLifeTime and improving European Healthcare through cell-based interceptive medicineLifeTime aims to track, understand and target human cells during the onset and progression of complex diseases and their response to therapy at single-cell resolution. This mission will be implemented through the development and integration of single-cell multi-omics and imaging, artificial intelligence and patient-derived experimental disease models during progression from health to disease. Analysis of such large molecular and clinical datasets will discover molecular mechanisms, create predictive computational models of disease progression, and reveal new drug targets and therapies. Timely detection and interception of disease embedded in an ethical and patient-centered vision will be achieved through interactions across academia, hospitals, patient-associations, health data management systems and industry. Applying this strategy to key medical challenges in cancer, neurological, infectious, chronic inflammatory and cardiovascular diseases at the single-cell level will usher in cell-based interceptive medicine in Europe over the next decade. Read the full article on Nature
|
||
Chris Marine elected as an EMBO Excellence in Life Sciences MemberCongratulations to Chris MarineChris has been elected as an Embo - Excellence in Life Sciences member! Chris is one of the 63 leading scientists that EMBO gives the lifetime honour of membership in recognition of his remarkable achievements in life sciences. Read more on https://vib.be/news/vib-scientists-jean-christophe-marine-jan-steyaert-and-alain-goossens-elected-embo-members |